Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alkermes (ALKS) and MacroGenics (MGNX).
Alkermes (ALKS)
J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Alkermes on September 18. The company’s shares closed last Monday at $17.37.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 19.9% and a 55.7% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Alkermes has an analyst consensus of Hold, with a price target consensus of $19.17, implying an 8.1% upside from current levels. In a report released today, H.C. Wainwright also maintained a Hold rating on the stock with a $23.00 price target.
See today’s analyst top recommended stocks >>
MacroGenics (MGNX)
In a report released today, Jonathan Chang from Leerink Partners maintained a Buy rating on MacroGenics, with a price target of $38.00. The company’s shares closed last Monday at $27.68, close to its 52-week high of $32.18.
According to TipRanks.com, Chang is a 5-star analyst with an average return of 30.0% and a 58.1% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Revolution Medicines.
MacroGenics has an analyst consensus of Moderate Buy, with a price target consensus of $33.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
